Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca combo

​Eli Lilly and Company has reported results from the BRUIN CLL-322 Phase III trial, assessing Jaypirca, combined with venetoclax and rituximab, against venetoclax and rituximab alone in patients with r/r CLL/SLL.

The post Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca combo appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

FDA approves Bayer’s Ambelvist contrast agent
ALK’s EURneffy secures MHRA approval for anaphylaxis treatment
FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment
Fleming Initiative and Cepheid begin TRACE-CPE study on rapid CPE testing
First patient treated in Airiver Medical’s RESTORE-2 trial for CRS

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us